HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the second quarter ended June 30, 2025. “Our core business continues to strengthen as we execute on our $130 million EBITDA improvement plan,” said Aric Coffman, CEO of P3. “While we faced prior period headwinds, we've successfully managed medical cost trends to remain flat while imp
Related Questions
How does P3’s performance and cost management compare to its main competitors in the population health management space?
Is there any updated guidance for revenue, EBITDA, or EPS for the rest of 2025?
How does the reported $130 million EBITDA improvement plan compare to prior guidance and what are the updated expectations for Q3 and FY2025?
What specific headwinds impacted the prior period and are they expected to recur in upcoming quarters?
Did the company achieve its medical cost trend goal of staying flat, and how does that compare to industry benchmarks?
What were the actual revenue and EBITDA figures for Q2 2025, and how do they compare to consensus estimates?
What is the current cash position and debt maturity profile following the Q2 results?
How did the core business segments (e.g., Medicare Advantage, Medicaid) perform individually, and what are the growth trends?
What impact will the Q2 results have on the company’s valuation multiples relative to peers?
Are there any significant changes to the company's capital allocation strategy (e.g., share buybacks, dividend, M&A) following the results?